Abstract
This body of work highlighted a potential strategy of using HER3 antibodies in combination with standard chemotherapy agents for treating patients with either KRAS wild-type or KRAS mutant metastatic colorectal cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have